Guardian Pharmacy Preliminary Q4 Net Profit Slips Despite Rise In Revenue; Pre-Market Stock Down

Guardian Pharmacy Service a

19.35 USD 2.16%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Guardian Pharmacy Services, Inc. (GRDN) on Monday reported a decline in preliminary net profit for the fourth quarter. However, the company registered an increase in revenue.

For the three-month period to December 31, 2024, Guardian Pharmacy expects net profit of $10.1 to $11.1 million, a year-on-year decrease of $3.5 to $4.5 million. This was primarily due to an income tax provision expense of $5 to $6 million.

Revenue is expected to be around $338.6 million, up around 20.5 percent from the same period last year, helped by organic growth of the business and the acquisitions of Heartland Pharmacy and Freedom Pharmacy.

In addition, revenue was positively impacted by an increase in flu and Covid-19 vaccinations administered through clinics in certain long-term care facilities that the company serves.

Looking ahead, the company expects adjusted EBITDA of $97 to $101 million, with revenue of $1.330 to $1.350 billion.

GRDN was down by 9.95 percent at $18.01 in the pre-market trade on the New York Stock Exchange.